RAS mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data

George Kafatos, Daniela Niepel, Kimberley Lowe, Sophie Jenkins-Anderson, Hal Westhead, Tamer Garawin, Zuzana Traugottová, Antonios Bilalis, Edit Molnar, J. Tímár, Erika Toth, Nikolaos Gouvas, George Papaxoinis, Samuel Murray, Nadia Mokhtar, Hana Vosmikova, Pavel Fabian, Alena Skalova, Piotr Wójcik, Andrzej TysarowskiMario Barugel, J. Han Van Krieken, Jörg Trojan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. Materials & methods: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. Results: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. Conclusion: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.

Original languageEnglish
Pages (from-to)751-760
Number of pages10
JournalBiomarkers in Medicine
Volume11
Issue number9
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Meta-Analysis
Tumors
Colorectal Neoplasms
Mutation
Research
Neoplasms
Therapeutics

Keywords

  • anti-EGFR
  • BRAF
  • KRAS
  • mCRC
  • metastatic colorectal cancer
  • NRAS
  • prevalence
  • RAS
  • real world

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Kafatos, G., Niepel, D., Lowe, K., Jenkins-Anderson, S., Westhead, H., Garawin, T., ... Trojan, J. (2017). RAS mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data. Biomarkers in Medicine, 11(9), 751-760. https://doi.org/10.2217/bmm-2016-0358

RAS mutation prevalence among patients with metastatic colorectal cancer : A meta-analysis of real-world data. / Kafatos, George; Niepel, Daniela; Lowe, Kimberley; Jenkins-Anderson, Sophie; Westhead, Hal; Garawin, Tamer; Traugottová, Zuzana; Bilalis, Antonios; Molnar, Edit; Tímár, J.; Toth, Erika; Gouvas, Nikolaos; Papaxoinis, George; Murray, Samuel; Mokhtar, Nadia; Vosmikova, Hana; Fabian, Pavel; Skalova, Alena; Wójcik, Piotr; Tysarowski, Andrzej; Barugel, Mario; Van Krieken, J. Han; Trojan, Jörg.

In: Biomarkers in Medicine, Vol. 11, No. 9, 01.09.2017, p. 751-760.

Research output: Contribution to journalArticle

Kafatos, G, Niepel, D, Lowe, K, Jenkins-Anderson, S, Westhead, H, Garawin, T, Traugottová, Z, Bilalis, A, Molnar, E, Tímár, J, Toth, E, Gouvas, N, Papaxoinis, G, Murray, S, Mokhtar, N, Vosmikova, H, Fabian, P, Skalova, A, Wójcik, P, Tysarowski, A, Barugel, M, Van Krieken, JH & Trojan, J 2017, 'RAS mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data', Biomarkers in Medicine, vol. 11, no. 9, pp. 751-760. https://doi.org/10.2217/bmm-2016-0358
Kafatos, George ; Niepel, Daniela ; Lowe, Kimberley ; Jenkins-Anderson, Sophie ; Westhead, Hal ; Garawin, Tamer ; Traugottová, Zuzana ; Bilalis, Antonios ; Molnar, Edit ; Tímár, J. ; Toth, Erika ; Gouvas, Nikolaos ; Papaxoinis, George ; Murray, Samuel ; Mokhtar, Nadia ; Vosmikova, Hana ; Fabian, Pavel ; Skalova, Alena ; Wójcik, Piotr ; Tysarowski, Andrzej ; Barugel, Mario ; Van Krieken, J. Han ; Trojan, Jörg. / RAS mutation prevalence among patients with metastatic colorectal cancer : A meta-analysis of real-world data. In: Biomarkers in Medicine. 2017 ; Vol. 11, No. 9. pp. 751-760.
@article{4a621534aa834159aee890d86f2b9200,
title = "RAS mutation prevalence among patients with metastatic colorectal cancer: A meta-analysis of real-world data",
abstract = "Aim: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. Materials & methods: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. Results: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6{\%} (95{\%} CI: 38.8-48.5{\%}); ranging from 33.7{\%} (95{\%} CI: 28.4-39.3{\%}) to 54.1{\%} (95{\%} CI: 51.7-56.5{\%}) between sources. Conclusion: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.",
keywords = "anti-EGFR, BRAF, KRAS, mCRC, metastatic colorectal cancer, NRAS, prevalence, RAS, real world",
author = "George Kafatos and Daniela Niepel and Kimberley Lowe and Sophie Jenkins-Anderson and Hal Westhead and Tamer Garawin and Zuzana Traugottov{\'a} and Antonios Bilalis and Edit Molnar and J. T{\'i}m{\'a}r and Erika Toth and Nikolaos Gouvas and George Papaxoinis and Samuel Murray and Nadia Mokhtar and Hana Vosmikova and Pavel Fabian and Alena Skalova and Piotr W{\'o}jcik and Andrzej Tysarowski and Mario Barugel and {Van Krieken}, {J. Han} and J{\"o}rg Trojan",
year = "2017",
month = "9",
day = "1",
doi = "10.2217/bmm-2016-0358",
language = "English",
volume = "11",
pages = "751--760",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - RAS mutation prevalence among patients with metastatic colorectal cancer

T2 - A meta-analysis of real-world data

AU - Kafatos, George

AU - Niepel, Daniela

AU - Lowe, Kimberley

AU - Jenkins-Anderson, Sophie

AU - Westhead, Hal

AU - Garawin, Tamer

AU - Traugottová, Zuzana

AU - Bilalis, Antonios

AU - Molnar, Edit

AU - Tímár, J.

AU - Toth, Erika

AU - Gouvas, Nikolaos

AU - Papaxoinis, George

AU - Murray, Samuel

AU - Mokhtar, Nadia

AU - Vosmikova, Hana

AU - Fabian, Pavel

AU - Skalova, Alena

AU - Wójcik, Piotr

AU - Tysarowski, Andrzej

AU - Barugel, Mario

AU - Van Krieken, J. Han

AU - Trojan, Jörg

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Aim: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. Materials & methods: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. Results: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. Conclusion: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.

AB - Aim: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. Materials & methods: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. Results: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8-48.5%); ranging from 33.7% (95% CI: 28.4-39.3%) to 54.1% (95% CI: 51.7-56.5%) between sources. Conclusion: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.

KW - anti-EGFR

KW - BRAF

KW - KRAS

KW - mCRC

KW - metastatic colorectal cancer

KW - NRAS

KW - prevalence

KW - RAS

KW - real world

UR - http://www.scopus.com/inward/record.url?scp=85029806830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029806830&partnerID=8YFLogxK

U2 - 10.2217/bmm-2016-0358

DO - 10.2217/bmm-2016-0358

M3 - Article

C2 - 28747067

AN - SCOPUS:85029806830

VL - 11

SP - 751

EP - 760

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 9

ER -